2022
Animal Models to Investigate the Impact of Flavors on Nicotine Addiction and Dependence
Bagdas D, Kebede N, Zepei AM, Harris L, Minanov K, Picciotto MR, Addy NA. Animal Models to Investigate the Impact of Flavors on Nicotine Addiction and Dependence. Current Neuropharmacology 2022, 20: 2175-2201. PMID: 35611777, PMCID: PMC9886843, DOI: 10.2174/1570159x20666220524120231.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2019
Regulation of aggressive behaviors by nicotinic acetylcholine receptors: Animal models, human genetics, and clinical studies
Lewis AS, Picciotto MR. Regulation of aggressive behaviors by nicotinic acetylcholine receptors: Animal models, human genetics, and clinical studies. Neuropharmacology 2019, 167: 107929. PMID: 32058178, PMCID: PMC7080580, DOI: 10.1016/j.neuropharm.2019.107929.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNicotinic acetylcholine receptorsClinical studiesAnimal modelsAcetylcholine receptorsNeuropsychiatric disordersAggressive behaviorEffects of nAChRsAlpha 7 nAChRsSignificant side effectsHuman laboratory studiesLigand-gated ion channelsPsychopharmacological treatmentSide effectsMultiple key questionsHuman patientsNicotine NeuropharmacologyPredatory aggressionCHRNA7 geneHuman geneticsHuman genetic studiesPatientsNAChRsSevere aggressionIon channelsReceptors
2017
The Effect of Treatment with Guanfacine, an Alpha2 Adrenergic Agonist, on Dopaminergic Tone in Tobacco Smokers: An [11C]FLB457 PET Study
Sandiego CM, Matuskey D, Lavery M, McGovern E, Huang Y, Nabulsi N, Ropchan J, Picciotto MR, Morris ED, McKee SA, Cosgrove KP. The Effect of Treatment with Guanfacine, an Alpha2 Adrenergic Agonist, on Dopaminergic Tone in Tobacco Smokers: An [11C]FLB457 PET Study. Neuropsychopharmacology 2017, 43: 1052-1058. PMID: 28944773, PMCID: PMC5854798, DOI: 10.1038/npp.2017.223.Peer-Reviewed Original ResearchConceptsTobacco smokersGuanfacine treatmentPositron emission tomographyTobacco smokingDA releaseDopaminergic toneDopamine releaseAmphetamine-induced DA releaseTobacco smoking cessationCortical dopamine releaseExtrastriatal brain regionsAlpha2-adrenergic agonistExtrastriatal dopamine releaseEffect of treatmentBaseline BPNDSmoking cessationReceptor radiotracerAdrenergic agonistsPET scansAnimal modelsBrain regionsEmission tomographyPET studiesDopamine signalingSmokers
2015
Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states
Picciotto MR, Lewis AS, van Schalkwyk GI, Mineur YS. Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states. Neuropharmacology 2015, 96: 235-243. PMID: 25582289, PMCID: PMC4486625, DOI: 10.1016/j.neuropharm.2014.12.028.Peer-Reviewed Original ResearchConceptsNicotinic acetylcholine receptorsNicotinic medicationsAcetylcholine receptorsNicotinic agentsRole of nAChRsEffects of nicotineBehavioral statesSelf-medicate symptomsNicotinic effectsClinical trialsClinical studiesMood disordersPsychiatric disordersAnimal modelsAffective disordersMedicationsTobacco productsAnxiety regulationRelated constructsMental statesReceptorsDisordersNAChRsNicotineMood
2013
High-affinity nicotinic acetylcholine receptor expression and trafficking abnormalities in psychiatric illness
Lewis AS, Picciotto MR. High-affinity nicotinic acetylcholine receptor expression and trafficking abnormalities in psychiatric illness. Psychopharmacology 2013, 229: 477-485. PMID: 23624811, PMCID: PMC3766461, DOI: 10.1007/s00213-013-3126-5.Peer-Reviewed Original ResearchConceptsPsychiatric illnessNicotinic acetylcholine receptor expressionPre-clinical animal modelsMultiple psychiatric illnessesChronic nicotine exposureHigh-affinity nAChRsAcetylcholine receptor expressionNicotinic receptor subtypesNovel therapeutic agentsHuman psychiatric illnessCholinergic dysfunctionClinical featuresNicotine exposurePatient populationCholinergic systemNicotine intakeReceptor expressionReceptor subtypesMood disordersTobacco usePharmacological agentsAnimal modelsPsychiatric diseasesAcetylcholine receptorsIllnessCholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior
Mineur YS, Obayemi A, Wigestrand MB, Fote GM, Calarco CA, Li AM, Picciotto MR. Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 3573-3578. PMID: 23401542, PMCID: PMC3587265, DOI: 10.1073/pnas.1219731110.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcholinesteraseAnimalsAntidepressive AgentsAnxietyBehavior, AnimalCholinergic AntagonistsCholinergic NeuronsDependovirusDepressionFluoxetineGene Knockdown TechniquesHindlimb SuspensionHippocampusHumansMaleMiceMice, Inbred C57BLPhenotypePhysostigmineReceptors, CholinergicResilience, PsychologicalRNA, Small InterferingSignal TransductionStress, PsychologicalTime FactorsConceptsDepression-like behaviorShRNA-mediated knockdownSelective serotonin reuptake inhibitor fluoxetineSerotonin reuptake inhibitor fluoxetineAChE inhibitor physostigmineAdministration of fluoxetineBlockade of acetylcholinesteraseEndophenotypes of depressionHippocampal AChE activityAntidepressant-like effectsReuptake inhibitor fluoxetineAChE activityDepression-like phenotypeSymptoms of depressionSocial defeat paradigmHippocampal AChEMuscarinic antagonistCholinergic drugsInhibitor physostigmineCholinergic systemClinical trialsSystemic administrationMood disordersSystemic effectsAnimal models
2010
Cortico-Thalamic Connectivity is Vulnerable to Nicotine Exposure During Early Postnatal Development through α4/β2/α5 Nicotinic Acetylcholine Receptors
Heath CJ, King SL, Gotti C, Marks MJ, Picciotto MR. Cortico-Thalamic Connectivity is Vulnerable to Nicotine Exposure During Early Postnatal Development through α4/β2/α5 Nicotinic Acetylcholine Receptors. Neuropsychopharmacology 2010, 35: 2324-2338. PMID: 20736992, PMCID: PMC2955839, DOI: 10.1038/npp.2010.130.Peer-Reviewed Original ResearchConceptsDevelopmental nicotine exposureNicotine exposureNicotinic acetylcholine receptorsAcetylcholine receptorsΑ5 nicotinic acetylcholine receptorConstituents of smokeEarly post-natal periodPrimary addictive componentΑ5 nAChR subunitTobacco smoke exposureCortico-thalamic connectivityPost-natal periodEarly postnatal developmentPassive avoidance behaviorCorticothalamic neuronsAddictive componentCorticothalamic projectionsSmoke exposureReceptor subtypesNAChR subtypesDevelopmental exposureMouse modelNeurodevelopmental periodAnimal modelsBehavioral alterations
2008
Nicotine-induced plasticity during development: Modulation of the cholinergic system and long-term consequences for circuits involved in attention and sensory processing
Heath CJ, Picciotto MR. Nicotine-induced plasticity during development: Modulation of the cholinergic system and long-term consequences for circuits involved in attention and sensory processing. Neuropharmacology 2008, 56: 254-262. PMID: 18692078, PMCID: PMC2635334, DOI: 10.1016/j.neuropharm.2008.07.020.Peer-Reviewed Original ResearchConceptsDevelopmental nicotine exposureSmoke exposureNicotine exposureEndogenous cholinergic signalingTobacco smoke exposureSensory processingSensory processing deficitsNicotinic acetylcholine receptorsAttention deficit hyperactivity disorderCritical periodDeficit hyperactivity disorderPregnant womenCholinergic systemCholinergic signalingLong-term consequencesEpidemiological studiesAnimal modelsAcetylcholine receptorsSynaptic plasticityNeuropsychiatric conditionsHyperactivity disorderNicotineExposureProcessing deficitsBehavioral processes
2007
Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice
Mineur YS, Somenzi O, Picciotto MR. Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology 2007, 52: 1256-1262. PMID: 17320916, PMCID: PMC1959230, DOI: 10.1016/j.neuropharm.2007.01.006.Peer-Reviewed Original ResearchConceptsAntidepressant-like effectsAntidepressant-like propertiesAntidepressant efficacyNicotinic acetylcholine receptorsPartial agonistBasolateral amygdalaAcetylcholine receptorsHigh-affinity nicotinic acetylcholine receptorsC-Fos immunoreactivityNovel antidepressant drugsC-fos expressionPotential neurobiological correlatesAlpha3/Classical antidepressantsAntidepressant drugsRodent modelsImmunohistochemical analysisNeuronal activityAnimal modelsFull agonistAgonistsNeuronal systemsEfficacyNeurobiological correlatesCytisine
2006
Guidelines on nicotine dose selection for in vivo research
Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Damaj MI, Donny EC, Gardiner PS, Grady SR, Heberlein U, Leonard SS, Levin ED, Lukas RJ, Markou A, Marks MJ, McCallum SE, Parameswaran N, Perkins KA, Picciotto MR, Quik M, Rose JE, Rothenfluh A, Schafer WR, Stolerman IP, Tyndale RF, Wehner JM, Zirger JM. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology 2006, 190: 269-319. PMID: 16896961, DOI: 10.1007/s00213-006-0441-0.Peer-Reviewed Original ResearchConceptsRoute of administrationDose selectionAnimal modelsDose rangeNicotine replacement therapyChronic nicotine exposureDose-response relationshipDrug-taking behaviorTobacco exposureNicotine exposureCigarette smokingReplacement therapyVivo effectsChronic exposureNicotine metabolismVivo responseNonhuman primatesVivo studiesObjectivesThis reviewRegimenVivo researchAdministrationExposureGenetic backgroundReview
2003
Sex differences in response to oral amitriptyline in three animal models of depression in C57BL/6J mice
Caldarone BJ, Karthigeyan K, Harrist A, Hunsberger JG, Wittmack E, King SL, Jatlow P, Picciotto MR. Sex differences in response to oral amitriptyline in three animal models of depression in C57BL/6J mice. Psychopharmacology 2003, 170: 94-101. PMID: 12879206, DOI: 10.1007/s00213-003-1518-7.Peer-Reviewed Original ResearchConceptsAntidepressant-like effectsTail suspension testDuration of treatmentAntidepressant amitriptylineTransgenic miceChronic treatmentImmobility timeB6 miceDepression modelChronic AMI treatmentFemale B6 miceTricyclic antidepressant amitriptylineMechanism of actionAMI administrationOral amitriptylineAntidepressant treatmentControl miceLH paradigmSwim testFemale miceOral administrationAMI treatmentEscape latencySuspension testAnimal models
1999
Increased neurodegeneration during ageing in mice lacking high‐affinity nicotine receptors
Zoli M, Picciotto M, Ferrari R, Cocchi D, Changeux J. Increased neurodegeneration during ageing in mice lacking high‐affinity nicotine receptors. The EMBO Journal 1999, 18: 1235-1244. PMID: 10064590, PMCID: PMC1171214, DOI: 10.1093/emboj/18.5.1235.Peer-Reviewed Original ResearchConceptsHigh-affinity nicotine receptorsSpatial learningHippocampal pyramidal neuronsRegion-specific alterationsSerum corticosterone levelsPossible animal modelNicotinic acetylcholine receptorsPyramidal neuronsNeuronal survivalNicotine receptorsCholinergic systemEndocrine parametersControl animalsIncreased neurodegenerationAnimal modelsCorticosterone levelsAcetylcholine receptorsAlzheimer's diseaseDegenerative processCortical regionsMorris mazeCognitive deficitsMutant miceMiceBeta2 subunit